Logo Logo
Switch Language to German

Terheyden, Jan H.; Finger, Robert P.; Schmitz-Valckenberg, Steffen; Agostini, HansJürgen; Dahlke, Claudia; Kuehlewein, Laura; Lang, Gabriele E.; Pauleikhoff, Daniel; Wolf, Armin; Boettger, Michael K.; Luhmann, Ulrich F. O.; Asmus, Friedrich; Holz, Frank G.; Asmus, F.; Berger, M.; Binns, A.; Boettger, M.; Bouchet, C.; Brazier, J. E.; Butt, T.; Carapezzi, C.; Carlton, J.; Costa, M.; Crabb, D. P.; Cunha-Vaz, J.; Dunbar, H.; Durbin, M.; Finger, R.; Holz, F.; Hoyng, C.; Kraetzschmar, J.; Luhmann, U.; Luening, A.; Margaron, Ph.; Martinho, C.; Melicio, B.; Normand, G.; Rowen, D.; Rubin, G. S.; Sahel, J.; Sanchez, C. I.; Fernandes, D. Sanches; Schmid, M.; Schmitz-Valckenberg, S.; Skelly, A.; Terheyden, J.; Tufail, A.; Wojek, C. and Zamiri, P. (2019): MACUSTAR: Entwicklung und klinische Validierung von funktionellen, strukturellen und patientenberichteten Endpunkten bei intermediärer altersabhängiger Makuladegeneration. In: Ophthalmologe, Vol. 116, No. 12: pp. 1186-1193

Full text not available from 'Open Access LMU'.


Background. Currently, no validated clinical endpoints for treatment studies exist for intermediate age-related macular degeneration (iAMD). Objective. The European MACUSTAR study aims to develop and clinically validate adequate clinical endpoints for future treatment studies in iAMD and to identify early determinants of disease progression to late stage AMD. Material and methods. The MACUSTAR study protocol was developed by an international consortium of researchers from academia, the pharmaceutical industry and medical device companies. The MACUSTAR project is funded by the Innovative Medicines Initiative 2 (IMI2) of the European Union. Results. The MACUSTAR study consists of a cross-sectional and a longitudinal investigation. A total of 750 subjects with early, intermediate and late AMD as well as control subjects with no signs of AMD will be included with a follow-up period of 3 years. Overall, 20 European study centers are involved. Conclusion. The MACUSTAR project will generate large high-quality datasets, which will allow clinical validation of novel endpoints for future interventional trials in iAMD. The aim is that these endpoints will be accepted as suitable for medication approval studies by the regulatory authorities and that understanding of the disease process will be improved.

Actions (login required)

View Item View Item